ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0

NCT ID: NCT01539629

Last Updated: 2012-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This 3rd phase of the ELEVATE study. The study is collecting data from an implanted CRT-D device to evaluate a new feature for future heart failure devices.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ELEVATE 3.0 is an acute, prospective, multicenter feasibility study which is randomized within a patient test sequence and pulse width. The study is designed to characterize the performance of LVAT (Left Ventricular Authothreshold) feature.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Heart failure Autothreshold Pacing CRT-D recipients Left Ventricular evoked response signals

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulse Width

One group reflecting two different pulse widths.

Cardiac pacing

Intervention Type DEVICE

Cadiac pacing via a pulse generator and implaned intracardiac leads.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac pacing

Cadiac pacing via a pulse generator and implaned intracardiac leads.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

COGNIS PG.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law
* Patients who have a COGNIS CRT-D device implanted for at least 24 hours, with or without an active right atrial lead
* Patients who have an active LV bipolar or unipolar lead
* Patients who have an active RV defibrillation lead
* Patients who are willing and capable of participating in all testing associated with this Clinical Investigation

Exclusion Criteria

* Patients who have a COGNIS CRT-D that has less than or equal to one year of battery life remaining
* Patients who are pacemaker-dependent as defined as VVI 40 without intrinsic atrial or ventricular activity
* Patients who will not tolerate a pacing pause of up to 6 seconds
* Patients with a pre-existing unipolar pacemaker
* Patients who are unable or unwilling to maintain a supine or sitting position for 20-50 minutes
* Patients enrolled in any concurrent study, without Boston Scientific CRM written approval
* Women who are pregnant;women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kenneth L Ellenbogen, MD

Role: PRINCIPAL_INVESTIGATOR

Virginia Commonwealth University Health System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Genesis Medical Center

Davenport, Iowa, United States

Site Status

Cardiology Consultants of Philadelphia

Yardley, Pennsylvania, United States

Site Status

Virginia Commonwealth University Health System

Richmond, Virginia, United States

Site Status

Wheaton Franciscan Health Care

Wauwatosa, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ELEVATE 3.0

Identifier Type: -

Identifier Source: org_study_id